Afinitor In Pancreatic Tumors: ODAC Sees Consistent Efficacy, But Favors Limits On Use

The consistency of the progression-free survival benefit with Novartis’ Afinitor (everolimus) led FDA’s Oncologic Drugs Advisory Committee to support the drug’s approval for treatment of advanced pancreatic neuroendocrine tumors (PNET) despite questions about the statistical treatment of data in the pivotal study.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet